Recent developments include the announcement of a merger agreement with Indivior Pharmaceuticals to create a combined CNS company valued at approximately $2.2 billion, continued growth in sales of key products such as Qelbree, GOCOVRI, ONAPGO, and ZURZUVAE, and updates on clinical development programs and regulatory filings.

• On August 1, 2026, Supernus entered into a merger agreement with Indivior Pharmaceuticals to form a combined CNS company valued at approximately $2.2 billion; the combined company will be renamed Supernus, Inc. and continue trading under the ticker SUPN [N1].
• Q2 2026 net product sales increased 5% year-over-year to $165.7 million, with total revenues up 32% to $219.1 million [S2].
• Collaboration revenue from ZURZUVAE was $35.4 million in Q2 2026, with U.S. sales increasing approximately 53% compared to the same period in 2025 [N6].
• Net sales of Qelbree increased 15% to $89.2 million in Q2 2026, with prescription growth of 17% year-over-year [N6].
• Net sales of GOCOVRI increased 2% to $37.6 million in Q2 2026, with prescription growth of 9% year-over-year [N6].
• ONAPGO net product sales were $13.5 million in Q2 2026, with approximately 2,600 enrollment forms submitted by about 720 prescribers through July 2026 [N6].
• The company plans to submit a regulatory filing for a second supplier for ONAPGO in Q3 2026, with potential FDA approval by mid-2027 [S2].
• The company reported a net loss of $58.4 million and basic and diluted EPS of -$1.01 for Q2 2026 [S2].

Supernus has demonstrated growth in key product sales such as Qelbree, GOCOVRI, ONAPGO, and ZURZUVAE, supported by expanding prescriptions and market acceptance. The collaboration with Biogen for ZURZUVAE and the regulatory approvals in multiple jurisdictions for zuranolone enhance commercial potential. The merger with Indivior Pharmaceuticals creates a larger CNS-focused entity with combined resources and product portfolios. Ongoing clinical development of novel candidates targeting epilepsy, depression, and ADHD may expand future opportunities.

The company faces risks including regulatory approval challenges, market acceptance uncertainties, and competition from other CNS therapies. Dependence on collaboration partners for development, manufacturing, and commercialization may impact execution if partners underperform or terminate agreements. The company reported a net loss in Q2 2026 and may incur substantial costs related to clinical development and integration post-merger. Pricing pressures and healthcare reform policies could affect revenues. The merger is subject to regulatory approvals and customary closing conditions, which may delay or alter anticipated benefits.

Supernus Pharmaceuticals' moat is supported by its portfolio of FDA-approved CNS therapies addressing multiple neurological and psychiatric conditions, including first-in-class or only FDA-approved treatments such as ZURZUVAE for postpartum depression and ONAPGO for motor fluctuations in Parkinson's Disease. Strategic collaborations with Biogen and Shionogi provide access to commercialization expertise and geographic reach. The company's pipeline of novel CNS candidates and its diversified product base contribute to competitive positioning. However, reliance on third-party collaborators and regulatory approvals introduces execution risks.

• Regulatory Approval Risks: Supernus must obtain and maintain regulatory approvals for its products and pipeline candidates in multiple jurisdictions. Delays or failures in approvals could impair commercialization and growth.
• Collaboration Dependency: The company relies on partners such as Biogen, Shionogi, and Knight Therapeutics for development and commercialization. Failure or termination of these collaborations could disrupt operations and revenues.
• Market Acceptance and Competition: Products may not achieve or maintain broad market acceptance due to competition, safety concerns, reimbursement challenges, or prescriber and patient preferences.
• Financial and Integration Risks: The company reported net losses and may face financial strain from clinical development costs and merger integration. The merger with Indivior is subject to regulatory and closing risks.
• Healthcare Reform and Pricing Pressure: Changes in healthcare laws, pricing regulations, and reimbursement policies could negatively impact product pricing and revenues.

• Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system (CNS) diseases.
• The company has a diverse neuroscience portfolio including treatments for ADHD, Parkinson's Disease (PD) dyskinesia and hypomobility, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
• Supernus is developing novel product candidates for CNS disorders including SPN-817 (a selective acetylcholinesterase inhibitor for epilepsy), SPN-820 (an mTORC1 signaling enhancer for depression), and SPN-443 (a novel stimulant for ADHD).
• The company has several FDA-approved commercial products: Qelbree (viloxazine) for ADHD, GOCOVRI (amantadine) for PD dyskinesia and OFF episodes, ONAPGO (apomorphine infusion) for motor fluctuations in advanced PD, ZURZUVAE (zuranolone) for postpartum depression, APOKYN (apomorphine injection) for hypomobility in PD, Trokendi XR (topiramate) for epilepsy and migraine, Oxtellar XR (oxcarbazepine) for epilepsy, XADAGO (safinamide) for PD OFF episodes, and MYOBLOC (rimabotulinumtoxinB) for cervical dystonia and chronic sialorrhea.
• ZURZUVAE is the first oral treatment specifically indicated for adults with postpartum depression, approved by the FDA in August 2023 and commercially available in the U.S. since December 2023. It is jointly commercialized with Biogen in the U.S., with profits and losses shared equally.
• The company has collaboration agreements granting Biogen rights to develop and commercialize zuranolone outside the U.S., except in Japan, Taiwan, and South Korea where Shionogi holds rights.
• Shionogi received regulatory approval for zuranolone in major depressive disorder (MDD) in Japan in late 2025 and launched commercially in early 2026.
• Knight Therapeutics holds commercialization rights for Qelbree in Canada but has experienced regulatory setbacks.
• ONAPGO was approved by the FDA in February 2025 and launched in April 2025; net product sales were $13.5 million in Q2 2026 with approximately 2,600 enrollment forms submitted by about 720 prescribers through July 2026.
• The company plans to submit a regulatory filing for a second supplier for ONAPGO in Q3 2026, with potential FDA approval by mid-2027.
• Collaboration revenue from ZURZUVAE was $35.4 million in Q2 2026, representing 50% of Biogen's net revenues for the product; U.S. sales increased approximately 53% year-over-year in Q2 2026.
• Net sales of Qelbree increased 15% to $89.2 million in Q2 2026 compared to Q2 2025, with prescription growth of 17%.
• Net sales of GOCOVRI increased 2% to $37.6 million in Q2 2026 compared to Q2 2025, with prescription growth of 9%.
• The company reported total net product sales of $165.7 million in Q2 2026, a 5% increase from Q2 2025, and total revenues of $219.1 million in Q2 2026, a 32% increase from Q2 2025.
• Supernus entered into a merger agreement with Indivior Pharmaceuticals on August 1, 2026, creating a combined CNS company valued at approximately $2.2 billion; the combined company will be renamed Supernus, Inc. and continue trading under the ticker SUPN.
• The merger consideration involves an exchange ratio of 1.5401 Indivior shares per Supernus share, with Indivior paying a $1 billion special cash dividend prior to the merger.
• The combined company's board will consist of eight members, equally split between nominees from Indivior and Supernus, with Jack A. Khattar as CEO and Timothy C. Dec as CFO.
• The company had cash and cash equivalents of approximately $180 million as of June 30, 2026, current assets of $723.5 million, current liabilities of $347.4 million, resulting in a current ratio of 2.08 and a cash ratio of 1.58 as of that date.
• The company reported a net loss of $58.4 million and basic and diluted EPS of -$1.01 for Q2 2026.
• Supernus relies on collaborations and licensing agreements for development, manufacturing, and commercialization, including with Biogen, Shionogi, Knight Therapeutics, and others.
• The company faces risks related to regulatory approvals, market acceptance, competition, collaboration partner performance, and compliance with healthcare laws.
• The company is developing SPN-817 for epilepsy, SPN-820 for depression, and SPN-443 for ADHD, with ongoing and planned clinical trials.
• The company has experienced growth in sales of key products such as Qelbree, GOCOVRI, ONAPGO, and ZURZUVAE in recent quarters.
• The company’s commercial success depends partly on the performance of collaboration partners, regulatory approvals in various jurisdictions, and market acceptance of its products.
• The company’s recent merger with Indivior is subject to regulatory approvals and customary closing conditions.
• The company’s financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.